Pancreatic Cancer Research

ResearcherUniversity of California, Los AngelesActive in the last 2 years

Shigeki Nakagawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3994-4028; OpenAlex author ID A5056749064. Sources: OpenAlex.

Their work

Papers
25 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
52
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 6 papers · 2019: 3 papers · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 3 papers · 2024: 1 paper · 2025: 1 paper · 2026: 4 papers

Papers 25

  1. A case of pancreatic cancer with high microsatellite instability exhibiting rare clinical features. Co-author DOI 10.1007/s12328-025-02256-2↗
  2. A case of long-term survival in unresectable pancreatic cancer with BRCA germline mutation treated with platinum-based chemotherapy. Co-author DOI 10.1007/s12328-026-02359-4↗
  3. Neoadjuvant Chemotherapy Diminishes Ki-67 Overexpression and Persistent Overexpression Is a Poor Prognostic Factor in Pancreatic Ductal Adenocarcinoma After Pa… Co-author DOI 10.1097/mpa.0000000000002641↗
  4. A Case of Pancreatic Cancer with High Tumor Mutation Burden Showing a Remarkable Response to Pembrolizumab. Co-author DOI 10.70352/scrj.cr.26-0273↗
  5. Molecular Alterations Influencing the Prognostic Outcome in Small Pancreatic Cancer (≤2 cm). Co-author DOI 10.1097/mpa.0000000000002430↗
  6. Impairment of perioperative activities of daily living is associated with poor prognosis following pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s00423-024-03478-7↗
  7. Hyperglycaemia induces metabolic reprogramming into a glycolytic phenotype and promotes epithelial-mesenchymal transitions via YAP/TAZ-Hedgehog signalling axis… Co-author DOI 10.1038/s41416-022-02106-9↗
  8. The Prognostic Role of Serine Racemase in Patients With Pancreatic Cancer: A New Marker in Cancer Metabolism. Co-author DOI 10.1097/mpa.0000000000002210↗
  9. Statins exert anti-growth effects by suppressing YAP/TAZ expressions via JNK signal activation and eliminate the immune suppression by downregulating PD-L1 exp… Co-author PMID 37293171↗
  10. Thrombospondin-1 overexpression stimulates loss of Smad4 and accelerates malignant behavior via TGF-β signal activation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2022.101533↗
  11. High Expression of Bloom Syndrome Helicase is a Key Factor for Poor Prognosis and Advanced Malignancy in Patients with Pancreatic Cancer: A Retrospective Study. Co-author DOI 10.1245/s10434-022-11500-9↗
  12. Frailty is associated with poor prognosis after resection for pancreatic cancer. Co-author DOI 10.1007/s10147-021-01983-z↗
  13. High ARHGEF2 (GEF-H1) Expression is Associated with Poor Prognosis Via Cell Cycle Regulation in Patients with Pancreatic Cancer. First author DOI 10.1245/s10434-020-09383-9↗
  14. Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer. Co-author DOI 10.1007/s00535-018-01535-9↗
  15. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis. Co-author DOI 10.1111/cas.13874↗
  16. Cellular Senescence, Represented by Expression of Caveolin-1, in Cancer-Associated Fibroblasts Promotes Tumor Invasion in Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-07266-2↗
  17. Clinical usefulness of postoperative C-reactive protein/albumin ratio in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.amjsurg.2017.08.016↗
  18. Serum Marker Score Based on Prognostic Nutrition Index, Carcinoembryonic Antigen, and Carbohydrate Antigen 19-9 Is Associated With Recurrence for Patients Unde… Co-author DOI 10.1097/mpa.0000000000001146↗
  19. Downregulation of 15-hydroxyprostaglandin dehydrogenase by interleukin-1β from activated macrophages leads to poor prognosis in pancreatic cancer. Co-author DOI 10.1111/cas.13467↗
  20. Multiple Primary Cancers in Patients with Pancreatic Cancer. Co-author DOI 10.1177/000313481808401205↗
  21. Thoracic wall muscle metastasis from pancreatic cancer. Co-author DOI 10.1186/s40792-017-0393-0↗
  22. Cystic gastric metastasis from pancreatic cancer. Co-author DOI 10.1186/s40792-018-0443-2↗
  23. Pancreatic Cancer Arising From the Remnant Pancreas: Is It a Local Recurrence or New Primary Lesion? Co-author DOI 10.1097/mpa.0000000000000897↗
  24. Significance of P-cadherin overexpression and possible mechanism of its regulation in intrahepatic cholangiocarcinoma and pancreatic cancer. Co-author DOI 10.1111/cas.12732↗
  25. Impact of Postoperative Weight Loss on Survival After Resection for Pancreatic Cancer. Co-author DOI 10.1177/0148607114520992↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiromitsu Hayashi · 15 shared papers, 2015–2026 · strength 2.68
  2. Hirohisa Okabe · 12 shared papers, 2015–2026 · strength 1.84
  3. Yuki Kitano · 9 shared papers, 2018–2026 · strength 1.63
  4. Katsunori Imai · 14 shared papers, 2015–2023 · strength 1.39
  5. Rumi Itoyama · 7 shared papers, 2018–2026 · strength 1.33
  6. Kosuke Mima · 8 shared papers, 2021–2025 · strength 1.33
  7. Masaaki Iwatsuki · 4 shared papers, 2026 · strength 1.10
  8. Hideo Baba · 11 shared papers, 2015–2023 · strength 1.06
  9. Takanobu Yamao · 7 shared papers, 2018–2026 · strength 0.92
  10. Norio Uemura · 5 shared papers, 2021–2026 · strength 0.83
  11. Takayoshi Kaida · 6 shared papers, 2018–2024 · strength 0.83
  12. Akira Chikamoto · 11 shared papers, 2015–2019 · strength 0.77
  13. Zhao Liu · 5 shared papers, 2022–2023 · strength 0.76
  14. Tatsunori Miyata · 7 shared papers, 2018–2023 · strength 0.72
  15. Daisuke Hashimoto · 9 shared papers, 2015–2019 · strength 0.64
  16. Kazuki Matsumura · 4 shared papers, 2021–2023 · strength 0.56
  17. Yosuke Nakao · 4 shared papers, 2019–2025 · strength 0.56
  18. Masayo Tsukamoto · 6 shared papers, 2018–2023 · strength 0.55
  19. Toru Takematsu · 2 shared papers, 2025–2026 · strength 0.52
  20. Shinsei Yumoto · 2 shared papers, 2026 · strength 0.51
  21. Naoki Umezaki · 6 shared papers, 2018–2021 · strength 0.49
  22. Hiroki Sato · 3 shared papers, 2022–2023 · strength 0.45
  23. Yuki Adachi · 2 shared papers, 2024–2026 · strength 0.45
  24. Kota Arima · 6 shared papers, 2018–2019 · strength 0.43
  25. Kensuke Yamamura · 5 shared papers, 2018–2019 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.